Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
vyantbio.com

See what CB Insights has to offer

Business Relationships

10

Service Providers

3

VyantBio Service Providers

3 Service Providers

VyantBio has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Merger

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

VyantBio Partners & Customers

10 Partners and customers

VyantBio has 10 strategic partners and customers. VyantBio recently partnered with Cellaria on October 10, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

10/8/2018

Partner

Cellaria

United States

Cancer Genetics and Cellaria Partner on Precision Medicine Tools :: Cancer Genetics, Inc. (CGIX)

RUTHERFORD , N.J. , Oct. 08 , 2018 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics , and Cellaria , LLC , a scientific innovator that develops revolutionary new cancer models , today announced a new collaboration to develop extensive precision medicine tools and platform technologies to support the development of new cancer therapeutics .

3

9/25/2018

Vendor

Agilent Technologies

United States

Cancer Genetics Enters Supply Agreement with Agilent Technologies

25 , 2018 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics , today announced that it has signed a non-exclusive supply agreement with Agilent Technologies Inc. through which Agilent Technologies Inc. will manufacture Cancer Genetics , Inc. ' proprietary FISH probe reagents .

4

4/10/2017

Client

eFFECTOR Therapeutics

United States

Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs.

RUTHERFORD , N.J. & SAN DIEGO , C.A. , April 10 , 2017 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for oncology through molecular markers and diagnostics , announced today that it has been chosen by eFFECTOR Therapeutics , Inc. , a biopharmaceutical company developing selective translation regulators for the treatment of cancer , to provide clinical biomarker services for eFFECTOR Therapeutics , Inc. 's lead product candidate eFT508 .

3

1/17/2017

Partner

Lantern Pharma

United States

Subscribe to see more

Subscribe to see more

10

12/7/2016

Partner

BeiGene

China

Subscribe to see more

Subscribe to see more

10

Date

10/8/2018

9/25/2018

4/10/2017

1/17/2017

12/7/2016

Type

Partner

Vendor

Client

Partner

Partner

Business Partner

Cellaria

Agilent Technologies

eFFECTOR Therapeutics

Lantern Pharma

BeiGene

Country

United States

United States

United States

United States

China

News Snippet

Cancer Genetics and Cellaria Partner on Precision Medicine Tools :: Cancer Genetics, Inc. (CGIX)

RUTHERFORD , N.J. , Oct. 08 , 2018 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics , and Cellaria , LLC , a scientific innovator that develops revolutionary new cancer models , today announced a new collaboration to develop extensive precision medicine tools and platform technologies to support the development of new cancer therapeutics .

Cancer Genetics Enters Supply Agreement with Agilent Technologies

25 , 2018 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics , today announced that it has signed a non-exclusive supply agreement with Agilent Technologies Inc. through which Agilent Technologies Inc. will manufacture Cancer Genetics , Inc. ' proprietary FISH probe reagents .

Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs.

RUTHERFORD , N.J. & SAN DIEGO , C.A. , April 10 , 2017 -- Cancer Genetics , Inc. , a leader in enabling precision medicine for oncology through molecular markers and diagnostics , announced today that it has been chosen by eFFECTOR Therapeutics , Inc. , a biopharmaceutical company developing selective translation regulators for the treatment of cancer , to provide clinical biomarker services for eFFECTOR Therapeutics , Inc. 's lead product candidate eFT508 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

4

3

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.